4 results about "Bioreductive Agent" patented technology

The invention relates to the technical field of nano materials, in particular to catechol derivative ligands, gold nanoparticles modified by the catechol derivative ligands and application of the catechol derivative ligands. The catechol derivative modified gold nanoparticles provided by the invention can be used as a biological reducing agent, specifically, the specific value of GSH / GSSG in tumor cells is increased, the specific value of NADPH / NADP + is increased, the content of extracellular H2O2 is reduced, the content of GPx is increased, the content of MDA is reduced, and a reductive stress state is formed, so that the catechol derivative modified gold nanoparticles can be used as the biological reducing agent. In a reductive stress state, not only can the proliferation rate of tumor cells be inhibited, but also the mitomycin C can be activated, and the treatment effect of the mitomycin C on tumors can be improved.

This invention relates to the field of nanomaterials technology, specifically to a catechol derivative ligand and its modified gold nanoparticles and their applications. The catechol derivative-modified gold nanoparticles provided by this invention can act as bioreducing agents, specifically by increasing the GSH / GSSG ratio and NADPH / NADP ratio in tumor cells. + By adjusting the ratio, reducing extracellular H2O2 content, increasing GPx content, and decreasing MDA content, a reducing stress state is formed, thus enabling it to act as a biological reducing agent. Under reducing stress, it can not only inhibit the proliferation rate of tumor cells but also activate mitomycin C, enhancing the therapeutic effect of mitomycin C on tumors.

To provide compositions and methods for the treatment of immune-mediated cancer. [Solution] Disclosed herein are methods and compositions for enhancing the immune response to a solid tumor in a subject. In some embodiments, the method includes (a) administering a hypoxia-activated bioreducing agent (HABA) to the subject, (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject, or (ii) forming an embolism in one or more blood vessels supplying a solid tumor, and (c) administering an immune checkpoint inhibitor before, simultaneously with, or following step (b) in an amount effective in enhancing the immune response to the solid tumor compared to the immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.

A biogenic silver-zinc-copper oxide nanocomposite system for antibacterial applications, comprising: a) a biological precursor module configured to use citrus limetta peel extract as a bioreducing and stabilizing agent; b) a metal precursor module comprising silver nitrate, zinc sulfate and copper sulfate solutions; c) a reaction module configured to perform simultaneous co-reduction of the metal precursor solutions in the presence of the biological precursor in a single vessel to form a trimetallic silver-zinc-copper oxide nanocomposite; d) a thermal processing module configured to dry and stabilize the formed nanocomposite in powder form; e) a characterization module configured to confirm the formation, composition and morphology of the nanocomposite using analytical techniques; and f) an antibacterial evaluation module configured to evaluate the bactericidal activity of the nanocomposite against pathogenic microorganisms, g) wherein the system produces a stable, environmentally friendly trimetallic nanocomposite that exhibits improved antibacterial activity.